Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809238 | 0.89 | NOS1 (0.33) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL473544 | 0.89 | NOS1 (0.33) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL38661123 | 0.89 | CA2 (0.38) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL28058283 | 0.87 | KMT2A (0.36) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL8329644 | 0.87 | NOS1 (0.33) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL1058519 | 0.86 | CACNA2D1 (0.37) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL27742642 | 0.86 | GABRR1 (0.39) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL27978913 | 0.86 | GABRR1 (0.39) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL13312676 | 0.86 | NOS1 (0.32) | KMT2AMEN1GAANOS1NOS3 | |
| SCHEMBL28739490 | 0.86 | MEN1 (0.35) | KMT2AMEN1GAANOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744668-A2 | POLYNUCLEOTIDE CONSTRUCTS | Sirius Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20240247025-A1 | POLYNUCLEOTIDE CONSTRUCTS | SIRIUS THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4253395-A2 | PROCESSES FOR THE PREPARATION OF CARBOHYDRATE CONJUGATED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-2879718-B1 | PROCESSES FOR THE PREPARATION OF CARBOHYDRATE CONJUGATED RNA AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-6660870-B1 | Serotonergic compounds which possess agonist activity at 5-HT2 receptors effectively lower and control normal and elevated IOP and are useful for treating glaucoma | ALCON, INC. (CH) | 2003-12-09 | — | — | US | disclosed |
| WO-2001070705-A1 | 2-ACYLAMINOBENZIMIDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | disclosed |
| US-5242943-A | Administering as beta adrenoceptor blocking agents | Louis, William J. (AU) | 1993-09-07 | — | — | US | disclosed |
| US-5051445-A | Cardiovascular disorders such as antiarrhythmia or cardiotonic agents, adrenergic blocking agents | Louis, William J. (AU) | 1991-09-24 | — | — | US | disclosed |
| EP-0177515-B1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Louis, William John (AU) | 1989-05-31 | — | — | EP | disclosed |
| EP-0177515-A4 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ LTD (CH) | 1986-09-23 | — | — | EP | disclosed |
| EP-0177515-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ LTD (CH) | 1986-04-16 | — | — | EP | disclosed |
| WO-1985004403-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ LTD. (CH) | 1985-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247025-A1 | POLYNUCLEOTIDE CONSTRUCTS | PHAX, CD2BP2, PNKP | KMT2A 2827/4885MEN1 3999/4885GAA 1811/4885 |
| US-11981703-B2 | Polynucleotide constructs | PHAX, CPSF6, RNGTT | KMT2A 3891/4885MEN1 4565/4885GAA 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.